Innoviva Inc Market Cap ($1.53 Billion)
Market Cap & Net Worth: Innoviva Inc (INVA)
Innoviva Inc market cap. Innoviva Inc (NASDAQ:INVA) has a market capitalization of $1.53 Billion ($1.53 Billion) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6943 globally and #2164 in its home market, demonstrating a 1.53% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Innoviva Inc's stock price $21.26 by its total outstanding shares 72245485 (72.25 Million). Also see Innoviva Inc cash conversion from operations for how efficiently the company converts equity into cash flow.
Innoviva Inc Market Cap History (2015–2026)
Innoviva Inc market cap history from 2015 to 2026. Data shows growth from $761.47 Million to $1.54 Billion (8.25% CAGR). Check Innoviva Inc stock quote for real-time trading data and today's change.
Index Memberships
Innoviva Inc is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.06% | #197 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #778 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.08% | #116 of 263 |
|
S&P Small-Cap 600 Index
SML
|
$1.55 Trillion | 0.08% | #375 of 602 |
Weight: Innoviva Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Innoviva Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Innoviva Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Innoviva Inc net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
3.40x
Innoviva Inc's market cap is 3.40 times its annual revenue
Latest Price to Earnings (P/E) Ratio
5.33x
Innoviva Inc's market cap is 5.33 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $773.03 Million | $133.57 Million | $59.54 Million | 5.79x | 12.98x |
| 2017 | $1.03 Billion | $217.22 Million | $134.14 Million | 4.72x | 7.64x |
| 2018 | $1.26 Billion | $261.00 Million | $395.06 Million | 4.83x | 3.19x |
| 2019 | $1.02 Billion | $261.02 Million | $157.29 Million | 3.92x | 6.50x |
| 2020 | $895.12 Million | $336.79 Million | $224.40 Million | 2.66x | 3.99x |
| 2021 | $1.25 Billion | $391.87 Million | $265.85 Million | 3.18x | 4.69x |
| 2022 | $957.25 Million | $331.34 Million | $213.92 Million | 2.89x | 4.47x |
| 2023 | $1.16 Billion | $310.46 Million | $179.72 Million | 3.73x | 6.45x |
| 2024 | $1.25 Billion | $358.71 Million | $23.39 Million | 3.49x | 53.58x |
| 2025 | $1.44 Billion | $425.13 Million | $271.17 Million | 3.40x | 5.33x |
Competitor Companies of INVA by Market Capitalization
Companies near Innoviva Inc in the global market cap rankings as of November 5, 2026. Also see how large is Innoviva Inc's balance sheet for a full breakdown of the balance sheet.
Key companies related to Innoviva Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Innoviva Inc (2015–2026)
Market capitalization of Innoviva Inc from 2015 to today. Between 2015 and today, Innoviva Inc's market cap moved from $761.47 Million to $ 1.54 Billion, with a yearly change of 8.25%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.54 Billion | +6.35% |
| 2025 | $1.44 Billion | +15.22% |
| 2024 | $1.25 Billion | +8.17% |
| 2023 | $1.16 Billion | +21.06% |
| 2022 | $957.25 Million | -23.19% |
| 2021 | $1.25 Billion | +39.23% |
| 2020 | $895.12 Million | -12.50% |
| 2019 | $1.02 Billion | -18.85% |
| 2018 | $1.26 Billion | +22.97% |
| 2017 | $1.03 Billion | +32.62% |
| 2016 | $773.03 Million | +1.52% |
| 2015 | $761.47 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Innoviva Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.53 Billion USD |
| MoneyControl | $1.53 Billion USD |
| MarketWatch | $1.53 Billion USD |
| marketcap.company | $1.53 Billion USD |
| Reuters | $1.53 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Innoviva Inc
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The com… Read more